Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial Results

Advancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease ...
NeurologyLive

Overviewing Phase 3 NIMBLE Trial Design and Patient Population

Ali Habib, MD, a neuromuscular specialist at UCI Health, breaks down the phase 3 NIMBLE trial's patient population, four ...
BIOENGINEER

Cold agglutinin disease: rare anemia gets first approved drug as treatment map redrawn

A new review maps how a clonal B-cell disorder and complement-driven hemolysis define cold agglutinin disease, why steroids ...
BIOENGINEER

Touch May Ease Pain Through Brain Pathways Beyond the Spinal Gate

A new commentary argues that touch-induced analgesia arises from a dynamic brain-spinal cord network in which supraspinal and ...
via

Insight Named an OpenAI Advanced Partner to Accelerate Midmarket Enterprise AI Adoption

Insight Enterprises (NASDAQ: NSIT) today announced that it has been named an OpenAI Advanced Partner within the OpenAI Partner Network, reinforcing Insight's position as a provider of AI solutions for ...
Finanznachrichten

Compvide, Inc.: Compvide Announces Commercial Launch of CIMED and Presents New Research at European Meeting on Complement in Human Disease (EMCHD) 2026

Compvide, Inc. today announced the commercial launch of its CIMED platform. The CIMED-AP, CIMED-LP, and CIMED-CP kits assess the alternative, lectin, and classical complement pathways, respectively, ...
Yahoo Finance

Compvide Announces Commercial Launch of CIMED and Presents New Research at European Meeting on Complement in Human Disease (EMCHD) 2026

SEATTLE, October 21, 2026--(BUSINESS WIRE)--Compvide, Inc. today announced the commercial launch of its CIMED platform. The CIMED-AP, CIMED-LP, and CIMED-CP kits assess the alternative, lectin, and ...